143 related articles for article (PubMed ID: 25358681)
1. Expression of PTEN in endometrial liquid-based cytology.
Di Lorito A; Zappacosta R; Capanna S; Gatta DM; Rosini S; Schmitt FC
Acta Cytol; 2014; 58(5):495-500. PubMed ID: 25358681
[TBL] [Abstract][Full Text] [Related]
2. [Immunohistochemical expression of PTEN antigen: a new tool for diagnosis of early endometrial neoplasia].
Taranger-Charpin C; Carpentier S; Dales JP; Garcia S; Djemli A; Andrac L; Lavaut MN; Sferlazzo K; Boubli L
Bull Acad Natl Med; 2004; 188(3):415-27; discussion 427-9. PubMed ID: 15584653
[TBL] [Abstract][Full Text] [Related]
3. Liquid-based endometrial cytology: cyto-histological correlation in a population of 917 women.
Buccoliero AM; Gheri CF; Castiglione F; Garbini F; Barbetti A; Fambrini M; Bargelli G; Pappalardo S; Taddei A; Boddi V; Scarselli GF; Marchionni M; Taddei GL
Cytopathology; 2007 Aug; 18(4):241-9. PubMed ID: 17559564
[TBL] [Abstract][Full Text] [Related]
4. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
5. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
6. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
[TBL] [Abstract][Full Text] [Related]
7. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.
Garg K; Broaddus RR; Soslow RA; Urbauer DL; Levine DA; Djordjevic B
Int J Gynecol Pathol; 2012 Jan; 31(1):48-56. PubMed ID: 22123723
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
9. Expression of p53 in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 May; 42(5):416-22. PubMed ID: 24167025
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
Lin WM; Forgacs E; Warshal DP; Yeh IT; Martin JS; Ashfaq R; Muller CY
Clin Cancer Res; 1998 Nov; 4(11):2577-83. PubMed ID: 9829719
[TBL] [Abstract][Full Text] [Related]
11. Molecular alterations in endometrial archived liquid-based cytology.
Di Lorito A; Rosini S; Falò E; Gustapane S; Gomes M; Costa JL; Schmitt FC
Diagn Cytopathol; 2013 Jun; 41(6):492-6. PubMed ID: 22807394
[TBL] [Abstract][Full Text] [Related]
12. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
[TBL] [Abstract][Full Text] [Related]
13. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Westin SN; Ju Z; Broaddus RR; Krakstad C; Li J; Pal N; Lu KH; Coleman RL; Hennessy BT; Klempner SJ; Werner HM; Salvesen HB; Cantley LC; Mills GB; Myers AP
Mol Oncol; 2015 Oct; 9(8):1694-703. PubMed ID: 26045339
[TBL] [Abstract][Full Text] [Related]
14. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
15. Direct uterine sampling with the Tao brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia: a feasibility study.
Kipp BR; Medeiros F; Campion MB; Distad TJ; Peterson LM; Keeney GL; Halling KC; Clayton AC
Cancer; 2008 Aug; 114(4):228-35. PubMed ID: 18548528
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas.
Zhang X; Dong Y; Ti H; Zhao J; Wang Y; Li T; Zhang B
Hum Pathol; 2013 Nov; 44(11):2571-80. PubMed ID: 24071015
[TBL] [Abstract][Full Text] [Related]
17. Immunoexpression of the PTEN protein and matrix metalloproteinase-2 in endometrial cysts, endometrioid and clear cell ovarian cancer.
Brucka A; Szyłło K
Ginekol Pol; 2013 May; 84(5):344-51. PubMed ID: 23819399
[TBL] [Abstract][Full Text] [Related]
18. The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma.
Macwhinnie N; Monaghan H
Int J Gynecol Cancer; 2004; 14(5):938-46. PubMed ID: 15361207
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study.
Athanassiadou P; Athanassiades P; Grapsa D; Gonidi M; Athanassiadou AM; Stamati PN; Patsouris E
Int J Gynecol Cancer; 2007; 17(3):697-704. PubMed ID: 17504383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]